Prior research has documented significant upregulation of rpLP2 in systemic lupus erythematosus, severe hepatitis, nephritis, and certain malignancies, implying that dysregulated inflammatory responses are among its key pathogenic mechanisms (Ling et al., 2020; Artero-Castro et al., 2011). This evidence concerns the gene RPLP2 and systemic lupus erythematosus.